Abstract
Background
Until recently, there was no approved adjuvant therapy (AT) for renal cell carcinoma (RCC) unless sunitinib was approved in the US. We evaluated clinical opinion and estimated use regarding different treatment options and patient selection of AT in RCC patients based on current scientific data and individual experience in Germany.
Methods
We conducted an anonymous survey during a national urology conference in 01/2017. Answers of 157 urologists treating RCC patients could be included. Questions were related to practice setting, treatment of RCC, follow-up strategy, physicians’ personal opinion and individually different important parameters regarding S-TRAC and ASSURE-trial.
Results
82% were office based. 67% were located in larger cities. 83% reported that nephron-sparing surgery (NSS) was performed in tumors with diameter < 4 cm. Follow-up was done mainly in concordance with guideline recommendations. 68% treated an average of 2.9 patients/year with systemic therapy. Therapy was predominantly advocated using sunitinib (94%). Urologists were informed about S-TRAC and ASSURE-trial. For 47%, reported hazard ratio is the most important parameter to understand trial results followed by overall survival (OS) in 46%, disease-free survival in 38%, and results of other trials in 34%. The most convincing parameter to decide on AT is OS (69%). 62% placed their confidence in ASSURE over STRAC-trial. 44% would use AT for 12 months. Nodal involvement was the most common denominator for use of AT. 82% favor sunitinib as AT.
Conclusions
A minority of urologists would use AT and are more confident in ASSURE-trial. Reluctance of prescribing AT mainly is based on lack of OS data and conflicting trial results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Institute NC (2017) SEER stat facts sheets: kidney and renal pelvis cancer 2017. https://seer.cancer.gov/statfacts/html/kidrp.html. Accessed 21 July 2018
Ljungberg B, Bensalah K, Canfield S et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924
Patard JJ, Kim HL, Lam JS et al (2004) Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22(16):3316–3322
Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer 97(7):1663–1671
Haas NB, Manola J, Uzzo RG et al (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032):2008–2016
Janowitz T, Welsh SJ, Zaki K et al (2013) Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol 40(4):482–491
Pal SK, Haas NB (2014) Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist 19(8):851–859
Ravaud A, Motzer RJ, Pandha HS et al (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375(23):2246–2254
Motzer RJ, Jonasch E, Agarwal N et al (2017) Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN 15(6):804–834
U. S. Food and Drug Administration (2017) FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm585686.html. Accessed 2018
Lenis AT, Donin NM, Johnson DC et al (2018) Adjuvant therapy for high risk localized kidney cancer: emerging evidence and future clinical trials. J Urol 199(1):43–52
Kroeger N, Stenzl A, Burchardt M et al (2017) Adjuvant treatment of high-risk renal cell carcinoma: leaving the desert? Eur Urol 71(5):695–696
Motzer RJ, Haas NB, Donskov F et al (2017) Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 35(35):3916–3923
Battle D, Hammers H, Jonasch E et al (2018) MP66-17 patients perspectives on adjuvant therapy in renal cell carcinoma. J Urol 199(4):e875
Meissner MA, McCormick BZ, Karam JA et al (2018) Adjuvant therapy for advanced renal cell carcinoma. Expert Rev Anticancer Ther 18(7):663–671. https://doi.org/10.1080/14737140.2018.1469980
Gross-Goupil M, Kwon TG, Eto M et al (2018) Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 29(12):2371–2378
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical standards
This manuscript does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Spek, A., Szabados, B., Casuscelli, J. et al. Adjuvant therapy in renal cell carcinoma: the perspective of urologists. Int J Clin Oncol 24, 694–697 (2019). https://doi.org/10.1007/s10147-019-01398-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-019-01398-x